We are live on ! Find out more
Prosight Management

Prosight Management Portfolio holdings

AUM $515M Turnover 48.89%
1-Year Est. Return 2.95%
This Fund
S&P 500
This Quarter Est. Return
+2.67%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$342M
AUM Growth
+$131M
Cap. Flow
+$132M
Cap. Flow %
38.65%
Top 10 Hldgs %
60.71%
Holding
50
New
9
Increased
24
Reduced
4
Closed
13
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.8 years

Top Sells

Rank Stock Value
1
PRTA icon
Prothena
PRTA
+$21.1M
2
HZNP
Horizon Therapeutics
HZNP
+$8.84M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$6.11M
4
ALKS icon
Alkermes
ALKS
+$5.11M
5
CUE icon
Cue Biopharma
CUE
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
PCRX icon
1
Pacira BioSciences
PCRX
$35.2M 10.29%
877,586
+786,463
+863% +$32.5M
2023 Q1
1 quarter
MGTX icon
2
MeiraGTx Holdings
MGTX
$813M
$27.4M 8.02%
4,078,804
+2,589,887
+174% +$16.7M
2022 Q1
5 quarters
HUM icon
3
Humana
HUM
$46.3B
$24.6M 7.21%
55,100
+31,100
+130% +$15.7M
2022 Q3
3 quarters
ORIC icon
4
Oric Pharmaceuticals
ORIC
$793M
$21.4M 6.27%
2,761,468
+1,216,468
+79% +$6.91M
2022 Q3
3 quarters
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$1.88B
$17.6M 5.15%
2,500,000
+1,425,407
+133% +$11.4M
2022 Q2
4 quarters
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$6.04B
$17.5M 5.11%
675,000
+107,174
+19% +$2.85M
2022 Q1
5 quarters
LKFT icon
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.25B
$17M 4.97%
417,500
+42,000
+11% +$1.71M
2021 Q1
9 quarters
ABCL icon
8
AbCellera Biologics
ABCL
$3.6B
$16.5M 4.82%
2,550,000
+1,796,472
+238% +$12.3M
2022 Q3
3 quarters
NBIX icon
9
Neurocrine Biosciences
NBIX
$16.5B
$16M 4.69%
170,000
+90,000
+113% +$8.79M
2023 Q1
1 quarter
KURA icon
10
Kura Oncology
KURA
$674M
$14.2M 4.16%
+1,343,359
New +$15.9M
2023 Q2
0 quarters
CNC icon
11
Centene
CNC
$33.4B
$13.2M 3.86%
195,670
+34,266
+21% +$2.29M
2023 Q1
1 quarter
ADCT icon
12
ADC Therapeutics
ADCT
$193M
$12M 3.51%
5,583,900
+2,326,540
+71% +$5.23M
2022 Q3
3 quarters
KZR icon
13
DELISTED
Kezar Life Sciences
KZR
$11.4M 3.34%
465,192
+145,192
+45% +$3.78M
2021 Q1
9 quarters
QDEL icon
14
QuidelOrtho
QDEL
$657M
$9.15M 2.68%
110,468
+62,113
+128% +$5.44M
2022 Q1
5 quarters
PRTA icon
15
Prothena
PRTA
$429M
$8.19M 2.4%
120,000
-327,092
-73% -$21.1M
2020 Q3
11 quarters
NSTG
16
DELISTED
NanoString Technologies
NSTG
$8.1M 2.37%
+2,000,000
New +$14.8M
2023 Q2
0 quarters
OPCH icon
17
Option Care Health
OPCH
$4.75B
$7.66M 2.24%
235,780
+80,880
+52% +$2.44M
2022 Q4
2 quarters
UNH icon
18
UnitedHealth
UNH
$314B
$7.21M 2.11%
15,000
+4,065
+37% +$1.99M
2022 Q4
2 quarters
NARI icon
19
DELISTED
Inari Medical
NARI
$6.9M 2.02%
118,684
+56,603
+91% +$3.57M
2023 Q1
1 quarter
STTK icon
20
Shattuck Labs
STTK
$455M
$6.58M 1.93%
2,109,620
+87,952
+4% +$255K
2021 Q3
7 quarters
LBPH icon
21
DELISTED
Longboard Pharmaceuticals
LBPH
$5.39M 1.58%
734,897
-165,703
-18% -$1.25M
2023 Q1
1 quarter
MDT icon
22
Medtronic
MDT
$129B
$5.29M 1.55%
+60,000
New +$5.17M
2023 Q2
0 quarters
ALKS icon
23
Alkermes
ALKS
$7.87B
$4.62M 1.35%
147,554
-168,611
-53% -$5.11M
2022 Q3
3 quarters
LENZ icon
24
LENZ Therapeutics
LENZ
$101M
$4.42M 1.29%
242,857
+117,619
+94% +$2.35M
2022 Q3
3 quarters
ERAS icon
25
Erasca
ERAS
$4.83B
$4.3M 1.26%
1,557,370
+378,280
+32% +$1.08M
2023 Q1
1 quarter

Similar funds

Prosight Management's Q2 2023 Portfolio in Review

As of Q2 2023, Prosight Management held 50 positions worth $342M, up 62% from $211M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Prosight Management deployed $132M of net new capital in Q2 2023, opening 9 new positions and adding to 24 existing holdings. Its largest new stake was Kura Oncology: 1,343,359 shares worth $14.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Prothena, an estimated $21.1M trimmed.

  • Prosight Management's largest Q2 2023 buy was Kura Oncology: 1,343,359 shares worth $14.2M.
  • Prosight Management added most to Pacira BioSciences in Q2 2023, an estimated $32.5M increase.
  • Prosight Management's biggest Q2 2023 reduction was Prothena, cutting an estimated $21.1M.
  • Prosight Management fully exited Horizon Therapeutics in Q2 2023, selling an estimated $8.84M.
  • Prosight Management's ten largest holdings make up 61% of its $342M portfolio in Q2 2023.
  • Prosight Management opened 9 new positions and closed 13 in Q2 2023.
  • Prosight Management's portfolio value rose 62% quarter-over-quarter to $342M.

Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.